Neurocrine Biosciences Q4 earnings topped forecasts, but revenue slightly missed. Analysts see Ingrezza's long-term growth ...

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while ...

Neurocrine Biosciences, Inc.’s NBIX share price has dipped by 18.53%, which has investors questioning if this is right time ...

Neurocrine Biosciences Inc. shares dived 18.53 percent on Friday, a third consecutive day, as investors digested the ...

Neurocrine Biosciences (($NBIX)) has held its Q4 earnings call. Read on for the main highlights of the call. Neurocrine Biosciences’ earnings call ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $169.43, a high estimate of $190.00, and a low estimate of $148.00. Observing a ...

Neurocrine Biosciences stock opened at $150.10 on Tuesday. The stock has a market cap of $15.20 billion, a price-to-earnings ratio of 40.24 and a beta of 0.33. The company’s 50-day moving ...

Neurocrine Biosciences, Inc. has a 52-week low of $110.95 and a 52-week high of $157.98. The firm has a market cap of $15.20 billion, a P/E ratio of 40.24 and a beta of 0.33. Analyst Upgrades and ...

We recently compiled a list of the 12 Best Low Risk High Growth Stocks to Invest In. In this article, we are going to take a look at where Neurocrine Biosciences, Inc.

Kevin Charles Gorman, a director at Neurocrine Biosciences Inc. (NASDAQ:NBIX), recently sold a significant portion of his holdings in the company. According to a recent SEC filing, Gorman sold ...

Neurocrine Biosciences Inc. (NASDAQ:NBIX), a biopharmaceutical company focused on developing treatments for neurological and endocrine-related diseases, has been navigating a complex landscape of ...